Zydus Cadila, an innovationdriven, global pharmaceutical company, announced that it has received the approval from the Drug Controller General of India for use of Saroglitazar Mg in the treatment of Type II Diabetes Mellitus as an add on therapy with Metformin. The drug was previously approved in the year 2013 for the treatment of Hypertriglyceridemia and Diabetic Dyslipidemia in India. More
than 1 Million patients are being treated with LipaglynTM.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
